Sangamo Therapeutics, Inc.SGMO was a big mover last session, as the company saw its shares rise more than 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 27% in the past one-month time frame.
The move came after the company made a deal with the Kite division of Gilead Sciences to team up on cancer treatments.
The company has seen no estimate revisions over the past few weeks and the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Sangamo Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Sangamo Therapeutics, Inc. Price
A better-ranked stock in the Medical - Biomedical and Genetics industry is Bioverativ Inc. BIVV , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don't miss your chance to get in on these long-term buys.